Literature DB >> 16906736

Validated method for the determination of the ethanol consumption markers ethyl glucuronide, ethyl phosphate, and ethyl sulfate in human urine by reversed-phase/weak anion exchange liquid chromatography-tandem mass spectrometry.

Wolfgang Bicker1, Michael Lämmerhofer, Thomas Keller, Rainer Schuhmacher, Rudolf Krska, Wolfgang Lindner.   

Abstract

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of the ethanol consumption markers ethyl glucuronide (EtG), ethyl phosphate (EtP), and ethyl sulfate (EtS) in human urine was developed. A reversed-phase/weak anion exchange type stationary phase demonstrated particular suitability for the analysis of these highly polar acids. Sample preparation was minimized to centrifugation and dilution of urine prior to injection. The method was validated in the range of 5-750 microg.L(-1) with 1:20 and 1:1000 diluted urine, which corresponds to actual concentration ranges of 0.1-15 and 5-750 mg.L(-1) in undiluted samples. Method validation was carried out using six different lots of human urine. Over the entire calibration range intraday and interday precision (each n = 5, three concentration levels per dilution factor) adopted values between 0.6 and 4.7% and 0.8 and 12.1%, relative standard deviation, respectively. Corresponding accuracy values ranged between 94.2 and 113.5% and 86.6 and 110.9%, respectively. Matrix effects (absolute/relative) were found to be present in minor extent (approximately -30% to +15% MS/MS signal alterations) and were well corrected by the employed isotopically labeled internal standards. The validated assay was applied to urine samples of a drinking study as well as postmortem specimens. It was possible to assess the principal potential of EtP as ethanol consumption marker. Elevated concentration levels were found in real samples; however, EtP seems to be less sensitive compared to the previously known ethanol phase II conjugates EtG and EtS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906736     DOI: 10.1021/ac060680+

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

1.  Clinical (nonforensic) application of ethyl glucuronide measurement: are we ready?

Authors:  Peter Jatlow; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

2.  Novel ultra stable silica-based stationary phases for reversed phase liquid chromatography--study of a hydrophobically assisted weak acid cation exchange phase.

Authors:  Yu Zhang; Peter W Carr
Journal:  J Chromatogr A       Date:  2010-11-16       Impact factor: 4.759

3.  A high-performance liquid chromatographic-tandem mass spectrometric method for the determination of ethyl glucuronide and ethyl sulfate in urine validated according to forensic guidelines.

Authors:  M E Albermann; F Musshoff; B Madea
Journal:  J Chromatogr Sci       Date:  2012-01       Impact factor: 1.618

4.  Preliminary investigations on ethyl glucuronide and ethyl sulfate cutoffs for detecting alcohol consumption on the basis of an ingestion experiment and on data from withdrawal treatment.

Authors:  Maria Elena Albermann; Frank Musshoff; Elke Doberentz; Peter Heese; Markus Banger; Burkhard Madea
Journal:  Int J Legal Med       Date:  2012-06-30       Impact factor: 2.686

Review 5.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

Review 6.  Ethanol metabolism and effects: nitric oxide and its interaction.

Authors:  Xin-Sheng Deng; Richard A Deitrich
Journal:  Curr Clin Pharmacol       Date:  2007-05

7.  A novel and an effective analytical approach for the LC-MS determination of ethyl glucuronide and ethyl sulfate in urine.

Authors:  Donata Favretto; Alessandro Nalesso; Giampietro Frison; Guido Viel; Pietro Traldi; Santo Davide Ferrara
Journal:  Int J Legal Med       Date:  2009-10-27       Impact factor: 2.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.